We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+95.73%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$643M
AUM Growth
+$316M
Cap. Flow
+$95.3M
Cap. Flow %
14.83%
Top 10 Hldgs %
78.08%
Holding
44
New
3
Increased
4
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
CRGX
CARGO Therapeutics
CRGX
+$69.9M
2
SRRK icon
Scholar Rock
SRRK
+$27.2M
3
NGNE icon
Neurogene
NGNE
+$18.2M
4
ABVX
Abivax
ABVX
+$8.66M
5
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$3.1M

Top Sells

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$11.9M
2
ACLX
Arcellx
ACLX
+$6.92M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$5.45M
4
IMCR icon
Immunocore
IMCR
+$4.2M
5
EYPT icon
EyePoint Inc
EYPT
+$3.45M

Sector Composition

Rank Sector Weight
1 Healthcare 99.57%
2 Financials 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
1
Scholar Rock
SRRK
$5.71B
$128M 19.85%
6,788,609
+2,189,781
+48% +$27.2M
RYZB
2
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$115M 17.85%
1,845,948
– –
CRGX
3
DELISTED
CARGO Therapeutics
CRGX
$95.4M 14.84%
+4,121,689
New +$69.9M
MLYS icon
4
Mineralys Therapeutics
MLYS
$2.35B
$38.9M 6.05%
4,519,361
– –
ACLX
5
DELISTED
Arcellx
ACLX
$25.6M 3.98%
460,441
-153,480
-25% -$6.92M
NGNE icon
6
Neurogene
NGNE
$696M
$24.6M 3.82%
+1,267,790
New +$18.2M
LENZ
7
LENZ Therapeutics
LENZ
$172M
$22.2M 3.45%
1,208,473
– –
NKTX icon
8
Nkarta
NKTX
$162M
$18.9M 2.94%
2,868,035
– –
SLRN
9
DELISTED
ACELYRIN
SLRN
$18.8M 2.93%
2,523,022
+141,443
+6% +$1.21M
ZYME icon
10
Zymeworks
ZYME
$1.68B
$15.2M 2.36%
1,458,875
– –
LYRA
11
DELISTED
LYRA THERAPEUTICS INC
LYRA
$14.6M 2.27%
55,605
– –
SYRS
12
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$13.9M 2.16%
1,786,427
+904,977
+103% +$3.1M
AVDL
13
DELISTED
Avadel Pharmaceuticals
AVDL
$13.7M 2.13%
967,527
– –
HLVX
14
DELISTED
HilleVax
HLVX
$12.8M 2%
799,274
– –
ABVX
15
Abivax
ABVX
$11B
$9.1M 1.41%
+850,000
New +$8.66M
RYTM icon
16
Rhythm Pharmaceuticals
RYTM
$7B
$7.94M 1.23%
172,647
-172,646
-50% -$5.45M
STRO icon
17
Sutro Biopharma
STRO
$379M
$7.19M 1.12%
167,558
– –
VRNA
18
DELISTED
Verona Pharma
VRNA
$6.91M 1.07%
347,500
– –
IOBT
19
DELISTED
IO Biotech
IOBT
$6.84M 1.06%
3,640,015
– –
INZY
20
DELISTED
Inozyme Pharma
INZY
$6.66M 1.04%
1,562,500
– –
TNGX icon
21
Tango Therapeutics
TNGX
$4.34B
$6.24M 0.97%
630,000
– –
GOSS icon
22
Gossamer Bio
GOSS
$66.5M
$5.59M 0.87%
6,130,268
– –
IMTX icon
23
Immatics
IMTX
$1.24B
$4.17M 0.65%
396,000
– –
PRME icon
24
Prime Medicine
PRME
$533M
$4.17M 0.65%
470,304
– –
JANX icon
25
Janux Therapeutics
JANX
$935M
$3.87M 0.6%
360,414
– –
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q4 2023 Portfolio in Review

As of Q4 2023, Samsara BioCapital held 44 positions worth $643M, up 97% from $327M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Samsara BioCapital deployed $95.3M of net new capital in Q4 2023, opening 3 new positions and adding to 4 existing holdings. Its largest new stake was CARGO Therapeutics: 4,121,689 shares worth $95.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Arcellx, an estimated $6.92M trimmed.

  • Samsara BioCapital's largest Q4 2023 buy was CARGO Therapeutics: 4,121,689 shares worth $95.4M.
  • Samsara BioCapital added most to Scholar Rock in Q4 2023, an estimated $27.2M increase.
  • Samsara BioCapital's biggest Q4 2023 reduction was Arcellx, cutting an estimated $6.92M.
  • Samsara BioCapital fully exited Intercept Pharmaceuticals, Inc. in Q4 2023, selling an estimated $11.9M.
  • Samsara BioCapital's ten largest holdings make up 78% of its $643M portfolio in Q4 2023.
  • Samsara BioCapital opened 3 new positions and closed 3 in Q4 2023.
  • Samsara BioCapital's portfolio value rose 97% quarter-over-quarter to $643M.

Based on Samsara BioCapital's 13F filing for Q4 2023, filed 14 Feb 2024.